- AUTOSHIP ORDERS INCREASE 42% IN MAY OVER APRIL -
VANCOUVER and MESA, AZ, June 4, 2012 /PRNewswire/ - Asantae Holdings International Inc. (TSXV: JVA, OTC: ASNHF) ("Asantae" or the "Company"), a producer and marketer of innovative nutritional products through a network of independent distributors, today reported robust growth in several key areas for May 2012.
Dan Lundell, Asantae's CEO, stated, "May's metrics represent a six-month trend of significant growth across all leading indicators. Our network has expanded based upon the impressive results of our weight-loss product RealW8™ and the business opportunity that Asantae offers to its Independent Affiliates. We expect profitability in Q2 and thereafter, and are excited about the revenue growth that we anticipate for the remainder of fiscal 2012."
Asantae Affiliate RecruitingAsantae added 24% to its active Affiliates and Preferred Customers in May. This represents over 750 new recruits for the month. Recruiting is a key indicator of momentum and growth. Auto Ship Growth Total Autoship (recurring) orders, an important gauge of retention and the health of the repeat consumption base of the business, are up 42% in May over April and have increased 243% since the beginning of 2012. RealW8™ Units Sold Asantae sold over 4900 units of RealW8™, an increase of 11% over April. This represents a 367% increase in monthly unit sales since the beginning of 2012. About Asantae Asantae Holdings International Inc. ( www.asantae.com) is a producer and marketer of innovative nutritional products through a network of independent distributors (Asantae Independent Affiliates). Asantae's flagship product RealW8™ addresses the primary threat to public health in the industrialized world; overweight and obesity. Asantae's approach to this threat is based on a body of research related to the brain chemistry of addiction, chronic low-grade inflammation and oxidative stresses which, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (obesity, heart disease, diabetes, stroke, some cancers, etc.). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.